Short answer
Immunome Inc. (IMNM) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$57M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- −100.0% YoY · −100.0% QoQ
- Net income
- −$57M
- −22.0% YoY · −32.4% QoQ
- EPS (diluted)
- −$0.66
- +12.0% YoY · −32.0% QoQ
Source: XBRL data from the Immunome Inc. (IMNM) Q3 2025 10-Q on SEC EDGAR. USD.
Immunome Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk due to recent acquisition of varegacestat, Phase 3 asset requiring additional clinical data before NDA submission
- Updated risk on capital sufficiency: cash expected to fund operations for ≥12 months from filing date amid volatile credit markets
- Regulatory risk: approval may include narrow indications, REMS requirements, or costly post-marketing trials affecting commercialization
- Operational risk: IM-3050 radioligand therapy faces supply chain, clinical site availability, and distribution challenges due to Lu-177 isotope
- Financial risk: reliance on equity financings including 2024 ATM Agreement; dilution risk and debt covenants may restrict corporate actions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Immunome Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.